Table 4. Clinical Side-Effects of the NPC Patient Cohort (Our Clinical Research).
| Items | Nivolumab + vaccinated (n = 54), n (%) | Nivolumab (n = 36), n (%) | P value |
|---|---|---|---|
| Side-effect of vaccination | |||
| Common side effects | |||
| Muscle pain | 44 (81.5) | NA | |
| Allergy | 4 (7.4) | NA | |
| Fever | 6 (11.1) | NA | |
| Nausea | 4 (7.4) | NA | |
| Headache | 4 (7.4) | NA | |
| Others | 6 (11.1) | NA | |
| irAE | |||
| Immune-related adverse effects | 50 (92.6) | 32 (88.9) | < 0.5 |
| ILD | 6 (11.1) | 4 (11.1) | |
| RCCEP | 10 (25.9) | 8 (22.2) | |
| Hepatitis | 6 (11.1) | 2 (5.6) | |
| Ulcerative colitis | 8 (14.8) | 6 (16.7) | |
| Hypothyroidism | 8 (14.8) | 4 (11.1) | |
| Others | 6 (22.2) | 4 (22.2) |
ILD: interstitial lung disease; irAE: immune-related adverse event; RCCEP: reactive cutaneous capillary endothelial proliferation.